Walgreens Boots Alliance, Inc. vs Geron Corporation: Efficiency in Cost of Revenue Explored

Cost Efficiency: Walgreens vs. Geron - A Decade of Insights

__timestampGeron CorporationWalgreens Boots Alliance, Inc.
Wednesday, January 1, 2014890100054823000000
Thursday, January 1, 2015957400076691000000
Friday, January 1, 20161469500087477000000
Sunday, January 1, 2017843700089052000000
Monday, January 1, 201812723000100745000000
Tuesday, January 1, 20195127200091915000000
Wednesday, January 1, 20205005200095905000000
Friday, January 1, 2021783000104442000000
Saturday, January 1, 2022868000104437000000
Sunday, January 1, 2023123740000112009000000
Monday, January 1, 2024121134000000
Loading chart...

Infusing magic into the data realm

Exploring Cost Efficiency: Walgreens Boots Alliance vs. Geron Corporation

In the ever-evolving landscape of corporate finance, understanding cost efficiency is paramount. This analysis delves into the cost of revenue trends for Walgreens Boots Alliance, Inc. and Geron Corporation from 2014 to 2023. Walgreens Boots Alliance, a retail pharmacy giant, consistently showcases a robust cost of revenue, peaking at approximately $112 billion in 2023, reflecting a 104% increase from 2014. In contrast, Geron Corporation, a biopharmaceutical company, exhibits a more volatile pattern, with a significant spike in 2023, reaching $123 million, a staggering 1,284% increase from 2022. This disparity highlights the contrasting business models and market dynamics of a retail behemoth versus a niche biotech firm. The data underscores the importance of strategic cost management in maintaining competitive advantage, especially in diverse sectors like retail and biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025